{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:31:18Z","timestamp":1791228678557,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Department of Pathology and Laboratory Medicine at Cedars-Sinai Medical Center"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.leukres.2013.07.028","type":"journal-article","created":{"date-parts":[[2013,8,17]],"date-time":"2013-08-17T08:15:53Z","timestamp":1376727353000},"page":"1271-1277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"title":["Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis"],"prefix":"10.1016","volume":"37","author":[{"given":"Munevver","family":"Cinar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FaridSaei","family":"Hamedani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhicheng","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bekir","family":"Cinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham M.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serhan","family":"Alkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"June (6)","key":"10.1016\/j.leukres.2013.07.028_bib0005","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.23176","article-title":"Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management","volume":"87","author":"Vose","year":"2012","journal-title":"Am J Hematol"},{"issue":"July (7)","key":"10.1016\/j.leukres.2013.07.028_bib0010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1440-1827.1997.tb04519.x","article-title":"Cyclin D1 overexpression in malignant lymphomas","volume":"47","author":"Nakamura","year":"1997","journal-title":"Pathol Int"},{"issue":"January (1)","key":"10.1016\/j.leukres.2013.07.028_bib0015","first-page":"26","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"Perez-Galan","year":"2010","journal-title":"Blood"},{"issue":"October (10)","key":"10.1016\/j.leukres.2013.07.028_bib0020","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"July (3)","key":"10.1016\/j.leukres.2013.07.028_bib0025","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/107327481201900307","article-title":"Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches","volume":"19","author":"Shah","year":"2012","journal-title":"Cancer Control"},{"issue":"February (2)","key":"10.1016\/j.leukres.2013.07.028_bib0030","doi-asserted-by":"crossref","first-page":"203","DOI":"10.18632\/oncotarget.426","article-title":"Novel targeted therapies for mantle cell lymphoma","volume":"3","author":"Alinari","year":"2012","journal-title":"Oncotarget"},{"issue":"November (11)","key":"10.1016\/j.leukres.2013.07.028_bib0035","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00277-012-1534-y","article-title":"Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting","volume":"91","author":"Witzens-Harig","year":"2012","journal-title":"Ann Hematol"},{"issue":"July (3)","key":"10.1016\/j.leukres.2013.07.028_bib0040","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1053\/j.seminhematol.2011.05.001","article-title":"Molecular targeted approaches in mantle cell lymphoma","volume":"48","author":"Weniger","year":"2011","journal-title":"Semin Hematol"},{"issue":"April (2)","key":"10.1016\/j.leukres.2013.07.028_bib0045","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3109\/08830185.2012.664797","article-title":"Bruton tyrosine kinase (BTK) and its role in B-cell malignancy","volume":"31","author":"Buggy","year":"2012","journal-title":"Int Rev Immunol"},{"issue":"January (7277)","key":"10.1016\/j.leukres.2013.07.028_bib0050","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"issue":"January (1)","key":"10.1016\/j.leukres.2013.07.028_bib0055","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"March (11)","key":"10.1016\/j.leukres.2013.07.028_bib0060","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"de Rooij","year":"2012","journal-title":"Blood"},{"issue":"June","key":"10.1016\/j.leukres.2013.07.028_bib0065","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1600-065X.2000.imr017504.x","article-title":"The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective","volume":"175","author":"Satterthwaite","year":"2000","journal-title":"Immunol Rev"},{"issue":"June (23)","key":"10.1016\/j.leukres.2013.07.028_bib0070","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.07.028_bib0075","series-title":"Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia","first-page":"88","author":"Wiestner","year":"2012"},{"issue":"July (29)","key":"10.1016\/j.leukres.2013.07.028_bib0080","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"April (4)","key":"10.1016\/j.leukres.2013.07.028_bib0085","doi-asserted-by":"crossref","first-page":"424","DOI":"10.5858\/2003-127-0424-COMCLC","article-title":"Characterization of 4 mantle cell lymphoma cell lines","volume":"127","author":"Amin","year":"2003","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.leukres.2013.07.028_bib0090","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/nprot.2006.238","article-title":"Analysis of apoptosis by propidium iodide staining and flow cytometry","volume":"1","author":"Riccardi","year":"2006","journal-title":"Nat Protoc"},{"issue":"January (1)","key":"10.1016\/j.leukres.2013.07.028_bib0095","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"July (3)","key":"10.1016\/j.leukres.2013.07.028_bib0100","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1053\/j.seminhematol.2011.04.001","article-title":"Molecular pathogenesis of mantle cell lymphoma: new perspectives and challenges with clinical implications","volume":"48","author":"Navarro","year":"2011","journal-title":"Semin Hematol"},{"issue":"January (2)","key":"10.1016\/j.leukres.2013.07.028_bib0105","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1182\/blood-2007-06-093401","article-title":"Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma","volume":"111","author":"Ek","year":"2008","journal-title":"Blood"},{"issue":"May (10)","key":"10.1016\/j.leukres.2013.07.028_bib0110","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.4049\/jimmunol.176.10.5715","article-title":"Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma","volume":"176","author":"Gururajan","year":"2006","journal-title":"J Immunol"},{"issue":"October (20)","key":"10.1016\/j.leukres.2013.07.028_bib0115","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features","volume":"72","author":"Navarro","year":"2012","journal-title":"Cancer Res"},{"issue":"February (5)","key":"10.1016\/j.leukres.2013.07.028_bib0120","first-page":"1182","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo","volume":"119","author":"Ponader","year":"2011","journal-title":"Blood"},{"issue":"August (6)","key":"10.1016\/j.leukres.2013.07.028_bib0125","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","article-title":"The B-cell receptor signaling pathway as a therapeutic target in CLL","volume":"120","author":"Woyach","year":"2012","journal-title":"Blood"},{"issue":"March (1)","key":"10.1016\/j.leukres.2013.07.028_bib0130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1600-065X.2008.00741.x","article-title":"Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain","volume":"228","author":"Mohamed","year":"2009","journal-title":"Immunol Rev"},{"issue":"August (4)","key":"10.1016\/j.leukres.2013.07.028_bib0135","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0952-7915(97)80107-0","article-title":"Role of Btk in B cell development and signaling","volume":"9","author":"Desiderio","year":"1997","journal-title":"Curr Opin Immunol"},{"issue":"May (5)","key":"10.1016\/j.leukres.2013.07.028_bib0140","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S1074-7613(00)80417-3","article-title":"Regulation of Btk function by a major autophosphorylation site within the SH3 domain","volume":"4","author":"Park","year":"1996","journal-title":"Immunity"},{"issue":"March (1)","key":"10.1016\/j.leukres.2013.07.028_bib0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11899-012-0147-9","article-title":"Ibrutinib (PCI-32765), the First BTK (Bruton's Tyrosine Kinase) Inhibitor in Clinical Trials","volume":"8","author":"Brown","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"issue":"April (1)","key":"10.1016\/j.leukres.2013.07.028_bib0150","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.12206","article-title":"The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib","volume":"161","author":"Dasmahapatra","year":"2013","journal-title":"Br J Haematol"},{"issue":"June","key":"10.1016\/j.leukres.2013.07.028_bib0155","article-title":"Targeting BTK with Ibrutinib in relapsed or refractory mantle-cell lymphoma","author":"Wang","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613002713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613002713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:58:40Z","timestamp":1758934720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212613002713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0145212613002713"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.07.028","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2013.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}